293 related articles for article (PubMed ID: 26769007)
41. Sensitivity and specificity of radiographic characteristics in atypical femoral fractures.
Adams AL; Xue F; Chantra JQ; Dell RM; Ott SM; Silverman S; Giaconi JC; Critchlow C
Osteoporos Int; 2017 Jan; 28(1):413-417. PubMed ID: 27766369
[TBL] [Abstract][Full Text] [Related]
42. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research.
Shane E; Burr D; Ebeling PR; Abrahamsen B; Adler RA; Brown TD; Cheung AM; Cosman F; Curtis JR; Dell R; Dempster D; Einhorn TA; Genant HK; Geusens P; Klaushofer K; Koval K; Lane JM; McKiernan F; McKinney R; Ng A; Nieves J; O'Keefe R; Papapoulos S; Sen HT; van der Meulen MC; Weinstein RS; Whyte M;
J Bone Miner Res; 2010 Nov; 25(11):2267-94. PubMed ID: 20842676
[TBL] [Abstract][Full Text] [Related]
43. Atypical Femoral Fracture in Rheumatoid Arthritis Patients Treated With Bisphosphonates: A Nested Case-Control Study.
Koh JH; Myong JP; Jung SM; Lee J; Kwok SK; Park SH; Ju JH
Arthritis Rheumatol; 2016 Jan; 68(1):77-82. PubMed ID: 26360133
[TBL] [Abstract][Full Text] [Related]
44. Incidence and Characteristics of Atypical Femoral Fractures: Clinical and Geometrical Data.
Mahjoub Z; Jean S; Leclerc JT; Brown JP; Boulet D; Pelet S; Grondin C; Dumont J; Belzile ÉL; Michou L
J Bone Miner Res; 2016 Apr; 31(4):767-76. PubMed ID: 26588590
[TBL] [Abstract][Full Text] [Related]
45. Influence of bisphosphonate therapy on bone geometry, volumetric bone density and bone strength of femoral shaft in postmenopausal women with rheumatoid arthritis.
Meinen R; Galli-Lysak I; Villiger PM; Aeberli D
BMC Musculoskelet Disord; 2016 Aug; 17():324. PubMed ID: 27491286
[TBL] [Abstract][Full Text] [Related]
46. Assessment of bone microarchitecture in postmenopausal women on long-term bisphosphonate therapy with atypical fractures of the femur.
Zanchetta MB; Diehl M; Buttazzoni M; Galich A; Silveira F; Bogado CE; Zanchetta JR
J Bone Miner Res; 2014 Apr; 29(4):999-1004. PubMed ID: 24115250
[TBL] [Abstract][Full Text] [Related]
47. Bisphosphonate use and atypical fractures of the femoral shaft.
Schilcher J; Michaëlsson K; Aspenberg P
N Engl J Med; 2011 May; 364(18):1728-37. PubMed ID: 21542743
[TBL] [Abstract][Full Text] [Related]
48. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use.
Meier RP; Perneger TV; Stern R; Rizzoli R; Peter RE
Arch Intern Med; 2012 Jun; 172(12):930-6. PubMed ID: 22732749
[TBL] [Abstract][Full Text] [Related]
49. Bisphosphonate therapy associated with bilateral atypical femoral fracture and delayed union.
Gárgyán I; Dózsai D; Csonka I; Rárosi F; Bodzay T; Csonka Á
Jt Dis Relat Surg; 2022; 33(1):24-32. PubMed ID: 35361077
[TBL] [Abstract][Full Text] [Related]
50. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.
Shane E; Burr D; Abrahamsen B; Adler RA; Brown TD; Cheung AM; Cosman F; Curtis JR; Dell R; Dempster DW; Ebeling PR; Einhorn TA; Genant HK; Geusens P; Klaushofer K; Lane JM; McKiernan F; McKinney R; Ng A; Nieves J; O'Keefe R; Papapoulos S; Howe TS; van der Meulen MC; Weinstein RS; Whyte MP
J Bone Miner Res; 2014 Jan; 29(1):1-23. PubMed ID: 23712442
[TBL] [Abstract][Full Text] [Related]
51. Bisphosphonates Use and Risk of Subtrochanteric and Diaphyseal Femur Fractures in Korea: Results from the National Claim Registry.
Lee YK; Byun DW; Jung SM; Kwon HY; Kim HY; Kim SH; Kim TY; Jang S; Ha YC
Calcif Tissue Int; 2019 Mar; 104(3):313-319. PubMed ID: 30446771
[TBL] [Abstract][Full Text] [Related]
52. Atypical femur fractures: 81 individual personal histories.
Schneider JP; Hinshaw WB; Su C; Solow P
J Clin Endocrinol Metab; 2012 Dec; 97(12):4324-8. PubMed ID: 23076349
[TBL] [Abstract][Full Text] [Related]
53. Duration-Dependent Increase of Human Bone Matrix Mineralization in Long-Term Bisphosphonate Users with Atypical Femur Fracture.
Farlay D; Rizzo S; Ste-Marie LG; Michou L; Morin SN; Qiu S; Chavassieux P; Chapurlat RD; Rao SD; Brown JP; Boivin G
J Bone Miner Res; 2021 Jun; 36(6):1031-1041. PubMed ID: 33434290
[TBL] [Abstract][Full Text] [Related]
54. Symptomatic atypical femoral fractures are related to underlying hip geometry.
Taormina DP; Marcano AI; Karia R; Egol KA; Tejwani NC
Bone; 2014 Jun; 63():1-6. PubMed ID: 24565751
[TBL] [Abstract][Full Text] [Related]
55. Differences in femur geometry and bone markers in atypical femur fractures and the general population.
Jung IJ; Kim JW
Sci Rep; 2021 Dec; 11(1):24149. PubMed ID: 34921200
[TBL] [Abstract][Full Text] [Related]
56. ATYPICAL FEMORAL FRACTURES AFTER LONG-TERM BISPHOSPHONATES THERAPY: CASE REPORT.
Găleşanu C; Mocanu V; Buzdugă C; Florescu A; Zaharia V; Lisnic V
Rev Med Chir Soc Med Nat Iasi; 2016; 120(1):114-8. PubMed ID: 27125082
[TBL] [Abstract][Full Text] [Related]
57. Diaphyseal femur fractures associated with bisphosphonate use.
Graham J; Irgit K; Smith WR; Bowen TR
Acta Orthop Traumatol Turc; 2013; 47(4):255-60. PubMed ID: 23999513
[TBL] [Abstract][Full Text] [Related]
58. The advantages of tomosynthesis for evaluating bisphosphonate-related atypical femur fractures compared to radiography.
Petraszko A; Siegal D; Flynn M; Rao SD; Peterson E; van Holsbeeck M
Skeletal Radiol; 2016 May; 45(5):615-23. PubMed ID: 26861160
[TBL] [Abstract][Full Text] [Related]
59. Incidence of serious side effects with intravenous bisphosphonate: a clinical audit.
Powell D; Bowler C; Roberts T; Garton M; Matthews C; McCall I; Davie M
QJM; 2012 Oct; 105(10):965-71. PubMed ID: 22753670
[TBL] [Abstract][Full Text] [Related]
60. The Sydney AFF Score: A Simple Tool to Distinguish Females Presenting With Atypical Femur Fractures Versus Typical Femur Fractures.
Crouch G; Dhanekula ND; Byth K; Burn E; Lau SL; Nairn L; Nery L; Doyle J; Graham E; Ellis A; Clifton-Bligh RJ; Girgis CM
J Bone Miner Res; 2021 May; 36(5):910-920. PubMed ID: 33528853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
